This discrepancy is probably due to the CKD-associated GH insensitivity of the kidneys, preventing GH actions on the glomerular cells and/or the considerably lower GH exposure in rhGH-treated patients, compared to GH excess in acromegalic patients and GH transgenic animals. This evidence concerns the gene GH1 and chronic kidney disease.